Overview

This trial is active, not recruiting.

Conditions substance abuse, hiv risk, criminogenic thinking, shame, guilt, empathy
Treatments mi plus ioc group intervention, motivational interview only
Phase phase 2
Sponsor George Mason University
Collaborator National Institute on Drug Abuse (NIDA)
Start date August 2009
End date December 2013
Trial size 200 participants
Trial identifier NCT01378936, R01DA014694, R01DA014694-11

Summary

The purpose of this study is to evaluate whether the Impact of Crime (IOC) group intervention with jail inmates reduces post-release recidivism, substance abuse, and HIV risk behavior.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking double blind (investigator, outcomes assessor)
Primary purpose treatment
Arm
(Experimental)
mi plus ioc group intervention Impact of Crime
45 minute Motivational Interview plus 16 session IOC intervention
(Experimental)
motivational interview only
45 minute Motivational Interview session

Primary Outcomes

Measure
Recidivism - Self report of arrests and undetected crimes
time frame: 3 months post-release
Recidivism - Self report of arrests and undetected crimes
time frame: 1 yr post-release
Recidivism - Self report of arrests and undetected crimes
time frame: 3 yr post-release
Recidivism - Self report of arrests and undetected crimes
time frame: 5 yr post-release
Recidivism -- official FBI records of arrests
time frame: 1 yr post-release
Recidivism -- official FBI records of arrests
time frame: 3 yr post-release
Recidivism -- official FBI records of arrests
time frame: 5 yr post-release

Secondary Outcomes

Measure
Changes in self-reported shame-proneness from baseline
time frame: changes from baseline to post tx and 3 mo, 1 yr, 3yr and 5 yr post-release
Changes in self-reported guilt proneness from baseline
time frame: changes from baseline to post tx, and 3 mo, 1 yr, 3 yr, 5 yr post-release
Changes from self-reported empathy from baseline
time frame: changes from baseline to post tx, 3 mo, 1 yr, 3 yr, 5 yr post-release
Changes from self-reported criminogenic thinking at baseline
time frame: changes from baseline to post tx, and 3 mo, 1 yr, 3 yr, 5 yr post-release
Changes in self-reported substance use and dependence from 1 yr pre-incarceration
time frame: changes from pre-incarceration to 3 mo, 1 yr, 3 yr, 5 yr post-release
Changes in self-reported HIV risk behavior (sex and IDU) from 1 year pre-incarceration
time frame: changes from pre-incarceration to 3 mo, 1 yr, 3 yr, 5 yr post-release

Eligibility Criteria

Male participants at least 18 years old.

Inclusion Criteria: - Must be 18 years or older - Must be male - Must be currently incarcerated jail inmate - Must be sentenced - Sentence must be short enough to serve out sentence at ADC - Release date must follow projected final session of treatment - Must speak, read, and write in English with sufficient proficiency to use workbook and participate in group sessions - Must be assigned to the jail's "general population" Exclusion Criteria: - Actively psychotic - Assigned "keep separate" from other group members

Additional Information

Official title Phase 2 RCT of Jail-Based Impact of Crime Intervention to Reduce Recidivism, Substance Abuse and HIV Risk Behavior
Principal investigator June P Tangney, Ph.D.
Description This project imports social-personality theory and research on moral emotions and cognitions to the applied problems of crime, substance abuse, and HIV risk behavior. The primary aim of this study, a Phase 2 Randomized Clinical Trial (RCT) of the restorative justice-inspired Impact of Crime (IOC) group intervention, is to examine the efficacy of treatment and to determine if changes in moral emotions and cognitions serve as mechanisms of action, explaining the impact of treatment involvement on reductions in post-release recidivism, substance abuse, and HIV risk behavior.
Trial information was received from ClinicalTrials.gov and was last updated in May 2013.
Information provided to ClinicalTrials.gov by George Mason University.